Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy

Abstract

Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC‐restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC‐independent manner, making them ideal candidates for developing allogeneic, off‐the-shelf cell‐based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of γδ T cells have been explored. In addition, γδ T cells can be engineered using different gene editing technologies that augment their tumor recognition abilities and antitumor functions. In this review, we outline the unique features of different subsets of human γδ T cells and their antitumor properties. We also summarize the past and the ongoing pre‐clinical studies and clinical trials utilizing γδ T cell‐based cancer immunotherapy.